Profile

Esther Dyson

Location: USA

Esther Dyson is a Swiss-born American journalist, author, businesswoman, investor, commentator and philanthropist. She is a leading angel investor focused on health care, open government, digital technology, biotechnology and outer space.

NUMBER

#19

Xs

637

Investments

184

Exits

97
Photo by areteindex.com
Unicorns
Overview
About Esther Dyson
Number of Portfolio Companies 6
Location USA

Esther Dyson is a Swiss-born American journalist, author, businesswoman, investor, commentator and philanthropist. She is a leading angel investor focused on health care, open government, digital technology, biotechnology and outer space. Dyson’s career focuses on health and continues to invest in health and technology startups. Dyson is executive founder of Wellville; a ten-year, nonprofit evidence-generating project devoted to implementing and refining models for investing in community health (not health care) that return profits to investors and health to the participants and their communities. Aside from that full-time role, Dyson spends her extra time investing in and nurturing start-ups, with a recent focus on health care (somewhat constrained to avoid conflicts with Wellville). On the health side, she is an investor in 23andMe (also a director), 4D Healthware, Applied Proteomics, Basil Health, Big Health, Care. Coach, Clover Health, Dopamine Labs, Eligible, Enso, Hawthorne Effect, Health Loop, HealthCelerate, HealthTap, 12Dx, Joany, Medesk, MedicaSafe, Equilibrium, Nanowear, NeuroGeneCES, Nuna, Omada Health, PatientsLikeMe, PatientsKnowBest, Prognos.ai, Proofpilot, Resilient, Sapiens, StartupHealth, Syllable, Tocagen, Turbine.al, Valkee, Vital Score, Wellpass (director) and Zipongo. She is also a member of the Board of Directors of Yandex.

No data.

Company name
ENTRY ROUND
VALUATION at entry ($M)
Xs
VALUATION 
Symantec
$55M
194,55
$10 700M
ClassPass
$10,91M
94,41
$1 030M
Block
Series A
$35,25M
83,69
$2 950M
Swvl
Series A
$20M
75
$1 500M
Evernote
Series A
$20M
61,5
$1 230M
23andMe
Series B
$125M
28
$3 500M

No data.

2024